116 related articles for article (PubMed ID: 6204752)
1. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Hutton JJ; Von Hoff DD; Kuhn J; Phillips J; Hersh M; Clark G
Cancer Res; 1984 Sep; 44(9):4183-6. PubMed ID: 6204752
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Leiby JM; Snider KM; Kraut EH; Metz EN; Malspeis L; Grever MR
Cancer Res; 1987 May; 47(10):2719-22. PubMed ID: 2436757
[TBL] [Abstract][Full Text] [Related]
3. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Boldt DH; Von Hoff DD; Kuhn JG; Hersh M
Cancer Res; 1984 Oct; 44(10):4661-6. PubMed ID: 6205751
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
5. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.
Noker PE; Duncan GF; El Dareer SM; Hill DL
Cancer Treat Rep; 1983 May; 67(5):445-56. PubMed ID: 6189605
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
Avramis VI; Champagne J; Sato J; Krailo M; Ettinger LJ; Poplack DG; Finkelstein J; Reaman G; Hammond GD; Holcenberg JS
Cancer Res; 1990 Nov; 50(22):7226-31. PubMed ID: 1699658
[TBL] [Abstract][Full Text] [Related]
8. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
Casper ES; Mittelman A; Kelson D; Young CW
Cancer Chemother Pharmacol; 1985; 15(3):233-5. PubMed ID: 2414021
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
Lathan B; Diehl V; Clark GM; von Hoff DD
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1891-5. PubMed ID: 2464493
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trials with fludarabine phosphate.
Von Hoff DD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
Weiss GR; Crowley J; Von Hoff DD; Taylor SA; Belt RJ; Coltman CA; Hynes HE; Costanzi JJ
Cancer Treat Rep; 1986 Sep; 70(9):1123-4. PubMed ID: 2427196
[No Abstract] [Full Text] [Related]
17. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Warrell RP; Berman E
J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
